Print Page     Close Window     

SEC Filings

6-K
AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document
 
 

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 23 ACI - 35 Anti - pTau therapeutic vaccine for AD – Phase 1b Indication Alzheimer’s disease Target Aggregated pTau Key results in pre - clinical studies Development status ▪ Clinical Phase 1b with interim data ▪ Acceptable safety and tolerability ▪ D ose - dependent and target - specific antibody response to pTau Licensed to ▪ High specific antibody response to pathogenic Tau ▪ Improvement of cognition, physical performance, behaviour and prolongation of survival ▪ Favorable safety profile with T - cell independent mode - of - action Immune response highly specific to phosphorylated - Tau Highly significant improvement of behavior (P301S) AC Immune unpublished data 0 1 2 3 4 pTau protein Tau protein O.D. at 1/100 dilution **** **** ACI-35 vaccinated mice pTau vs. Tau protein after 5 immunizations ACI-35 Tg mice ACI-35 wt mice PBS Tg mice 0.0 0.1 0.2 0.3 0.4 pTau protein Tau protein O.D. at 1/100 dilution ACI-37 vaccinated mice pTau vs. Tau protein after 5 immunizations ACI-35 Tg mice ACI-35 wt mice PBS Tg mice Note: Tg = Transgenic, wt = wild type 15 rpm ACI-R-40 Rotarod 5 M vehicle vs. ACI-35 vehicle ACI-35 0 5 10 15 p=0.02 Latency to fall (s)

 

© AC Immune 2015